Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Study broadens understanding of role of IDH1 and IDH2 mutations in AML

Study broadens understanding of role of IDH1 and IDH2 mutations in AML

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

Stem cell therapy can reduce risk of acute leukemia in affected individuals

Stem cell therapy can reduce risk of acute leukemia in affected individuals

p53 activation offers a novel strategy for cancer therapy

p53 activation offers a novel strategy for cancer therapy

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

No overall cancer risk in people who donate stem cells

No overall cancer risk in people who donate stem cells

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

MDS Foundation: Significant advances made in understanding, treating MDS, AML

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Study finds arsenic improves survival rate in APL patients

Study finds arsenic improves survival rate in APL patients

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel announces publication of sapacitabine in British Journal of Cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.